INDICATION
Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:
• who have intolerance to oral iron or have had unsatisfactory response to oral iron
• who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.

Please see additional Important Safety Information on page 2.
Please see Full Prescribing Information here.

To be eligible to participate in the MPS Copay Assistance Program, patients must:
○ Have commercial health insurance (i.e., health insurance offered through an employer; NOT Medicare, Medicare Advantage, Medicaid, TRICARE, or Veteran Affairs healthcare)
○ Reside in the United States or Puerto Rico
○ Be treated by a healthcare professional in the United States or Puerto Rico
○ Be 18 years of age or older
○ Be prescribed Monoferric for an on-label diagnosis

* If iron deficiency anemia returns within the coverage period, you would receive an annual maximum savings on OOP expenses of up to $4,000. Additional restrictions apply. Please see full Terms and Conditions at monoferric-patient-solutions.com.
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Monoferic is contraindicated in patients with a history of serious hypersensitivity to Monoferic or any of its components. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferic. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferic administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferic when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Monoferic is contraindicated in patients with prior serious hypersensitivity reactions to Monoferic or any of its components.

In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferic treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.

Iron Overload
Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not administer Monoferic to patients with iron overload.

ADVERSE REACTIONS
Adverse reactions were reported in 8.6% (172/2008) of patients treated with Monoferic. Adverse reactions related to treatment and reported by ≥1% of the treated patients were nausea (1.2%) and rash (1%). Adjudicated serious or severe hypersensitivity reactions were reported in 6/2008 (0.3%) patients in the Monoferic group. Hypophosphatemia (serum phosphate <2.0 mg/dL) was reported in 3.5% of Monoferic-treated patients in Trials 1 & 2.

To report adverse events, please contact Pharmacosmos at 1-888-828-0655. You may also contact the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information here.